Japan's CMIC files first product in orphan portfolio
This article was originally published in Scrip
Executive Summary
The pharmaceutical development services firm CMIC has filed for the approval in Japan of Buphenyl (sodium phenylbutyrate), the lead product in its development portfolio of orphan drugs for ultra-rare disorders.